New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer

FORUM - Trends in Experimental and Clinical Medicine

Volumn 12, Issue 1, 2002, Pages 4-15

  Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Cytotoxic agents; Metastasis; Molecular targeted therapies

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BMS 184476; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPOTHILONE DERIVATIVE; FLUOROURACIL DERIVATIVE; GEMCITABINE; HORMONE; LIPOSOME; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; PLATINUM DERIVATIVE; PREDNISONE; RALTITREXED; TAXANE DERIVATIVE; TRABECTEDIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HORMONE SENSITIVITY; HUMAN; METABOLIC DISORDER; METASTASIS; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NONHUMAN; RASH; REVIEW; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037001247     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Bishop JF et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol. 1999; 17: 2355-2364.
2. Nabholtz JM et al.. Prospective randomized trial of docetaxel versus mitomycin plus vinlastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 1999; 17: 1413-1424.
3. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. New Engl. J. Med. 2001; 344: 783.
4. Nabholtz JM et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC. Proc. Am. Soc. Clin. Oncol. 1999; 18: 127a (abs. 485).
5. Mackey JR et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first-line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2002; 21: 35a (abs. 137).
6. Jassem J et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J. Clin. Oncol. 2001; 19: 1707-1715.
7. Evans T et al. Phase III randomized trial of adriamycin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer: an ACCOG study. Proc. Am. Soc. Clin. Oncol. 2002; 21: 35a (abs. 136).
8. Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999; 17: 485-493.
9. Fumoleau P et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: results of a large phase II study. Proc. Am. Soc. Clin. Oncol. 2002; 21: (abs. 247).
10. Bergh J et al. A randomized phase II study of two different schedules of BMS-184476 - a novel taxane - in patients with previously anthracycline treated metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: 53a (abs. 210).
11. Ibrahim NK et al. Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in two multicenter phase II studies. Proc. Am. Soc. Clin. Oncol. 2002; 21: 53a (abs. 209).
12. Sabbatini P et al. Phase I/II study of PG-paclitaxel (CT-2103) in patients with recurrent ovarian cancer. Proceedings II European Spring Oncology Conference, 12-15 June 2002, Marbella, Málaga, Spain, 81.
13. Kudelka A et al. Phase I study of PG-paclitaxel (CT-2103) and cisplatin in patients with solid tumours: preliminary data. Proceedings II European Spring Oncology Conference, 12-15 June 2002, Marbella, Málaga, Spain, 78.
14. Fumoleau P et al. A dose finding and pharmacokinetic (PK) phase I study of a docetaxel polysorbate 80 free formulation (D-PSF) in advanced solid tumours. Proc. Am. Soc. Clin. Oncol. 2000; 19: 212a (abs. 826).
15. Goetz AD et al. Phase I and pharmacokinetic study of RPR 116258A, a novel taxane derivative, administered intravenously over 1 hour every three weeks. Proc. Am. Soc. Clin. Oncol. 2001; 20: 106a (abs. 419).
16. Sessa C et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann. Oncol. 2002; 13: 1140-1150.
17. Gelmon KA et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered an a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol. 2000; 18: 4098-4108.
18. Kurata T et al. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as 1-hour intravenous infusion in patients with advanced solid tumors. J. Clin. Oncol. 2000; 18: 3164-3171.
19. Trillet-Lenoir V et al. A phase II study of oral vinorelbine (NVBo) in first line locally advanced/metastatic breast cancer (ABC) chemotherapy. Final results. Proc. ECCO, Lisbon, 23/10/2001, S191 (abs. 700).
20. Debord JP. Phase I study of Vinflumine given as a 10-minute intravenous (IV) infusion on a weekly schedule in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2001; 20: 11a (abs. 441).
21. Roché H et al. Phase II studies of the novel epothilone BMS-247550 in patients (pts) with taxane-naïve or taxane-refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: (abs. 223).
22. Awada A et al. Phase I clinical and pharmacology study of the novel epothilone BMS-247550 given weekly in patients with advanced solid tumors. Proc. 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami, October 29-November 2. Clin. Cancer Res. 7: 3810s (abs. 779).
23. Schüller J et al. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 2000; 45: 291-297.
24. Pronk LC et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors. Br. J. Cancer. 2000 83: 22-29.
25. O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 2002; 20: 2812-2823.
26. Hortobagyi GN et al. A study of UFT + leucovorin (L) given as a twice daily (BID) regimen in the treatment of patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2001; 20: 47a (abs. 186).
27. Burstein HJ et al. New cytotoxic agents and schedules for advanced breast cancer. Semin. Oncol. 2002; 28: 344-358.
28. Carmichael J et al. Advanced breast cancer: a phase II trial with gemcitabine. J. Clin. Oncol. 1995; 13: 2731-2736.
29. Blackstein M et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 1996; 15: (abs. 135).
30. Possinger K et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999; 10: 155-162.
31. Awada A et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pretreated with both anthracyclines and taxanes. Eur. J. Cancer 2002; 38: 773-778.
32. Colomer R et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin. Oncol. 2000; 27 (1 Suppl. 2): 20-24.
33. Conte P et al. Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. Semin. Oncol. 28 (Suppl. 7): 15-17.
34. Miller KD et al. Gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001; 15 (2 Suppl. 3): 38-40.
35. Miles DW et al. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur. J. Cancer 2001; 37: 1366-1371.
36. Spielmann M et al. Activity of pemetrexed (ALIMTA ®, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clinical Breast Cancer 2001; 2: 47-51.
37. Llombart-Cussac A et al. A phase II trial of pemetrexed disodium (Alimta, LY23154)), in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxane (T) (salvage chemotherapy). Breast Cancer Res. Treat. 2000; 64: A526.
38. Mennel RG et al. Pemetrexed disodium (Alimta TM, LY231514, MTA) in advanced breast cancer (ABC) patients (pts) with prior anthracycline or anthracenedione, taxane and capecitabine treatment: a phase II study. Proc. Am. Soc. Clin. Oncol. 2001; 20: 49a (abs. 194).
39. Hanauske A. Development of pemetrexed in breast cancer using pharmacogenomics. Proceedings of Lilly Oncology Symposium, Oslo, July 2002, 28-29.
40. Smith I et al. A phase II study in advanced breast cancer: ZD1694 ("Tomudex") a novel direct and specific thymidylate synthase inhibitor. Br. J. Cancer 74: 479-481, 1996.
41. Sparano JA and Winer E. Liposomal Anthracyclines for Breast Cancer. Semin. Oncol. 2001; 28: (Suppl. 12) 32-40.
42. Harris L et al. Phase III study of TLC D-99 (Liposome encapsulated doxorubicin) vs free doxorubicin (Dox) in patients with metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. 1998; 17: 124a (abs. 474).
43. Batist G et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001; 19: 1444-1454.
44. Erdkamp F et al. Phase III study of TLC D-99 (Liposome Encapsulated Doxorubicin) plus cyclophosphamide vs epirubucin (EPI) plus cyclophosphamide (CPA) in patients with metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. 1999; 18: 121a (abs. 459).
45. Keller AM at al. Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen. Proc. Am. Soc. Clin. Oncol. 2001; 20: 30a (abs. 115).
46. Wigler N et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs doxorubicin for first-line treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: 45a (abs. 177).
47. Coleman R et al. An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx TM in metastatic breast cancer patients. 25th Annual San Antonio Breast Cancer Symposium, December 11-14, 2002, (submitted).
48. Perez EA et al. Randomized phase II study of 2 schedules of irinotecan (CPT-11) for patients (pts) with refractory metastatic breast cancer (MBC): an NCCTG cooperative group study. Proc. Am. Soc. Clin. Oncol. 2002; 21: (abs. 206).
49. Garufi C et al. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann. Oncol. 2001; 12: 179-182.
50. Fumoleau P et al. Open-label phase II study of oxaliplatin single agent with metastatic breast cancer after failure of anthracycline/taxane based chemotherapy. 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, 19-22 November 2002, abstract (submitted).
51. Delaloge S et al. A multistep randomized phase II/III trial comparing oxaliplatin (OXA) + 5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts). Proc. Am. Soc. Clin. Oncol. 2002; 21: (abs. 245).
52. Zelek L et al. Preliminary results of phase II study of ecteinascidin (ET-743) with the 24 hour continuous infusion q3 weeks schedule in pretreated advanced/metastatic breast cancer patients. Clin. Cancer Res. 2000; 6: 212.
53. Johnston SRD et al. Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: 35a (abs. 138).
54. Awada A et al. A phase I, clinical and pharmacokinetic trial of Zarnestra TM (farnesyl transferase inhibitor, R115777) and docetaxel: a promising combination in patients with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami, October 29 - November 2, 2001; (abs. 602).
55. Awada A et al. A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 49-9006 in patients with advanced solid cancers. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami, October 29 - November 2, 2001; (abs. 569).
56. Garfield D. Proteasome inhibitor PS-341 and docetaxel: sequence of administation may be crucial. The Lancet Oncology 2001; 2: 714.
57. Chan S et al. First report: a phase II study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol. 2002; 21: (abs. 175).
58. Sledge G et al. A phase II trial of single-agent rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 3a (5c).
59. Ranson M et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 2002; 20: 2240-2250.
60. Adams J et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 2615-2622.